BACKGROUND: The aim of this study was to estimate the cost-effectiveness of injectable extended-release naltrexone (XR-NTX) compared with methadone maintenance and buprenorphine maintenance treatment (MMT and BMT, respectively) for adult males enrolled in treatment for opioid dependence in the United States from the perspective of state-level addiction treatment payers. METHODS: A Markov model with daily time cycles was used to estimate the incremental cost per opioid-free day in a simulated cohort of adult males aged 18-65 over a 6-month period from the state health program perspective. RESULTS: XR-NTX is predicted to be more effective and more costly than methadone or buprenorphine in our target population, with an incremental cost per opioid-free day gained relative to the next-most effective treatment (MMT) of $72. The cost-effectiveness of XR-NTX relative to MMT was driven by its effectiveness in deterring opioid use while receiving treatment. CONCLUSIONS: XR-NTX is a cost-effective medication for treating opioid dependence if state addiction treatment payers are willing to pay at least $72 per opioid-free day.
BACKGROUND: The aim of this study was to estimate the cost-effectiveness of injectable extended-release naltrexone (XR-NTX) compared with methadone maintenance and buprenorphine maintenance treatment (MMT and BMT, respectively) for adult males enrolled in treatment for opioid dependence in the United States from the perspective of state-level addiction treatment payers. METHODS: A Markov model with daily time cycles was used to estimate the incremental cost per opioid-free day in a simulated cohort of adult males aged 18-65 over a 6-month period from the state health program perspective. RESULTS:XR-NTX is predicted to be more effective and more costly than methadone or buprenorphine in our target population, with an incremental cost per opioid-free day gained relative to the next-most effective treatment (MMT) of $72. The cost-effectiveness of XR-NTX relative to MMT was driven by its effectiveness in deterring opioid use while receiving treatment. CONCLUSIONS:XR-NTX is a cost-effective medication for treating opioid dependence if state addiction treatment payers are willing to pay at least $72 per opioid-free day.
Authors: Michael T French; Silvana K Zavala; Kathryn E McCollister; Holly B Waldron; Charles W Turner; Timothy J Ozechowski Journal: J Subst Abuse Treat Date: 2007-06-28
Authors: Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien Journal: Arch Gen Psychiatry Date: 2006-02
Authors: Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell Journal: Drug Alcohol Depend Date: 2003-09-10 Impact factor: 4.492
Authors: Sean M Murphy; Daniel Polsky; Joshua D Lee; Peter D Friedmann; Timothy W Kinlock; Edward V Nunes; Richard J Bonnie; Michael Gordon; Donna T Chen; Tamara Y Boney; Charles P O'Brien Journal: Addiction Date: 2017-04-12 Impact factor: 6.526
Authors: Hannah Fraser; Jon Zibbell; Thomas Hoerger; Susan Hariri; Claudia Vellozzi; Natasha K Martin; Alex H Kral; Matthew Hickman; John W Ward; Peter Vickerman Journal: Addiction Date: 2017-09-20 Impact factor: 6.526
Authors: Magdalena Cerdá; Mohammad S Jalali; Ava D Hamilton; Catherine DiGennaro; Ayaz Hyder; Julian Santaella-Tenorio; Navdep Kaur; Christina Wang; Katherine M Keyes Journal: Epidemiol Rev Date: 2022-01-14 Impact factor: 6.222
Authors: Elizabeth Beaulieu; Catherine DiGennaro; Erin Stringfellow; Ava Connolly; Ava Hamilton; Ayaz Hyder; Magdalena Cerdá; Katherine M Keyes; Mohammad S Jalali Journal: Value Health Date: 2020-10-26 Impact factor: 5.725
Authors: Jose Luis Burgos; Javier A Cepeda; James G Kahn; Maria Luisa Mittal; Emilio Meza; Raúl Rafael Palacios Lazos; Psyché Calderón Vargas; Peter Vickerman; Steffanie A Strathdee; Natasha K Martin Journal: Harm Reduct J Date: 2018-05-23
Authors: Van Phuong Hoang; Marian Shanahan; Nagesh Shukla; Pascal Perez; Michael Farrell; Alison Ritter Journal: BMC Health Serv Res Date: 2016-04-13 Impact factor: 2.655